Issue Date: July 13, 2009
Novavax In Vaccine Deal With Rovi
Novavax is licensing its recombinant virus-like-particle (VLP) vaccine technology to Madrid-based Rovi Pharmaceuticals for the development of vaccines under an $83 million program sponsored by the Spanish Ministry of Health. Novavax, based in Rockville, Md., says it is also negotiating a broader licensing deal with Rovi under which the Spanish firm will receive exclusive licenses to Novavax' technology to commercialize flu vaccines in Spain and Portugal and nonexclusive licenses for Europe, . . .
To view the rest of this content, please log in with your ACS ID.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society